newsfilter
← Latest News
PR Newswire·

Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease

- Treatment with SLS-005 demonstrated a 46% reduction in tau protein and an 18% reduction in NfL biomarker from baseline values within six months - Seelos has been selected to present these data at Neuroscience 2023 to